ADC Therapeutics and Freenome enter biomarker development collaboration

Image: Freenome’s platform will characterize tumor heterogeneity and systemic immune response to identify signatures from blood of DLBCL patients participating in ADC Therapeutics’ pivotal Phase II clinical trial. Photo: courtesy of Arek Socha from Pixabay.